• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Anumana's ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status

    inHEART's 3D Cardiac Modeling Tool Earns FDA Nod

    FDA OKs RapidAI's Pulmonary Embolism Triage, Notification Tool

    Kilo Health Invests 500,000 Euros in Pulsetto

    China to Strengthen Robotic Surgical Market With Second 5-Year Plan
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Injecting Neurostimulators into Blood Vessels (We Swear, It’s Not Sci-Fi)

    Understanding the Costs of Care in the OR

    Sick of Being Sick: Pandemic Fatigue Flares at AAOS

    Managing Critical Healthcare Supply Chains in Turbulent Times

    To Drive Value, Human Capital Leaders Turn to Outsourced Solutions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Xact Wire EDM Corp.

    Trademark Plastics Inc.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical

    Concise Engineering
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing in Dental Prosthodontics, Orthodontics, and Surgery

    What New Tech Can Improve Your Medical Manufacturing Plant?

    Why Medical Device Firms Must Navigate the Muddy Waters of ESG Requirements

    Medical Device Servicing vs. Remanufacturing

    Digital Marketplaces for Medical Equipment Come of Age
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Xact Wire EDM Corp.

    Trademark Plastics Inc.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical

    Concise Engineering
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Trends, Opportunities, and Drivers in Early-Stage Life Sciences Investing

    Despite trade wars and economic shifts in China and the EU, early-stage investing in life sciences remained strong in Q1 2019.

    Trends, Opportunities, and Drivers in Early-Stage Life Sciences Investing
    Related CONTENT
    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    • MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021
    • Olympus Corporation Launches Powerseal Advanced Bipolar Surgical Energy Products
    • Picarro Unveils EtO Gas Concentration Analyzer
    • Molli Surgical's Breast Tumor Marker
    Byron S. Kalogerou, Partner, McDermott Will & Emery09.06.19
    It’s a great time to be an early-stage life sciences company. Significant funding continues to roll into this sector, driven by legacy venture capital (VC) funds bringing in new dollars, new players that are out-raising their targets, and active corporate venture capital players. Despite trade wars and economic shifts in China and the EU, early-stage investing in life sciences, particularly in the biotechnology and medical devices sectors, remained strong in Q1 2019, improving quarter over quarter with more than $2.8 billion invested into the space. The confluence of funding and an innovation-friendly regulatory environment provide early-stage life sciences companies with ample opportunity to bring their solutions to market. This article explores the factors driving opportunity in this investment space, as well as how investors and companies can position themselves as attractive partners.

    Getting Innovation to Market and Subsectors to Watch
    Recent actions by the U.S. Congress and leadership at the U.S. Food and Drug Administration (FDA) have demonstrated regulatory support for innovative life sciences solutions. Numerous programs, such as the FDA’s Breakthrough Designation Program for medical devices and the Digital Health Precertification Program, among others, have allowed companies to work more closely with regulators, communicate with them prior to approval submissions, and bring products to market more rapidly, while still maintaining patient safety. These programs, which require fewer data submissions at the outset in exchange for increased post-market study and surveillance obligations, can allow companies with smaller budgets to get their product to market earlier.

    Coinciding with the shift in focus from treatment to cure, from status quo to innovation, the first generation of gene cell therapies have arrived, along with a new wave of digital health applications that employ artificial intelligence (AI) and machine learning (ML). New tools, diagnostics, and devices are reshaping the way patients receive treatment across the spectrum of care. These exciting breakthroughs are accelerating discovery and creating a better understanding of the mechanism of action—which, in turn, gives better insight into clinical outcomes, giving investors a more predictable return. Particularly ripe subsectors for investment as indicated by Q1 2019 performance and regulatory attention include:
    • AI and ML: From diagnosing tumors to matching patients to clinical trials, the staggering amount of data collected in the life sciences space presents numerous use cases for AI and ML solutions. While implementation challenges remain, a recent FDA white paper on its efforts to develop a framework for regulating AI products, along with two AI-based devices approved by the agency in 2018, are promising for investors and developers alike. Investors and analysts have taken note, with AI in the life sciences space valued at $902.1 million (forecasted 2019-2024).
    • Medical Devices: Funding for medical devices saw a 7 percent quarter over quarter increase to $701 million in Q1 2019. The FDA’s Breakthrough Device Program, which has granted 112 Breakthrough Designation Requests as of January 2019, is one example of the supportive regulatory environment and a contributing factor to the funding increases seen in this life sciences subsector.
    Transformation-Driven Partnerships: Evaluating and Attracting Targets
    Within this dynamic landscape, early-stage life sciences companies and investors are forming mutually profitable partnerships to bring transformative products to market faster and more efficiently. Life sciences companies can take strategic steps to enhance their value as a potential investment target. When evaluating targets, investors often look for the following elements:
    • Innovation and unmet need. Novel products, therapies, or approaches that address an unmet need in the market are good candidates for investment.
    • The right team. It is often easier to find good technology than good managers, according to some investors. A life sciences company with a well-run team and strong leadership in place makes for a more attractive investment partner. Effective leaders who can clearly articulate the path to commercialization and the cost to do so will attract investment dollars.
    • Cross-border application. More than ever, investors are looking for products that can enter multiple markets, including Europe and Asia Pacific, because an expanded geographic approach can increase returns. Devices and other products that have application to China’s burgeoning market are a particularly hot focus for investors.
    • Opportunities to add value. Many investors seek out targets that present compelling and quantifiable propositions to drive significant costs out of the healthcare system while improving health outcomes. Investors are not seeking opportunities for marginal savings, but rather transformative “move the needle” innovation.
    To set the stage for an effective investment partnership, life sciences companies should reach out early and often to potential investors, well before they are actually looking to raise capital. Attending industry and well-orchestrated partnering events like Life Science Nation’s RESI series can be a good opportunity to connect and develop relationships with a host of potential investors. Investors don’t just invest in a product—they invest in a team—so face-to-face interaction can lay valuable groundwork for a potential partnership. Curating those contacts through counsel, an accountant, and/or banker can reap dividends over time.

    In addition to evaluating whether a partnership is a good fit from a leadership and culture perspective, investors will often consider the following questions when evaluating a potential target—being prepared to speak directly and clearly to these points, as well as to specific goals for the partnership, will allow for a much more fruitful conversation with a potential investor.
    • What is the regulatory risk? What will it take to get the company through the next regulatory milestones in all relevant jurisdictions? Is it reasonable to expect the device or product to be approved globally at the same time, or will there be regulatory lag? What level of investment will it take to get the product into a clinic and generate the necessary clinical data? Investors today are increasingly conditioning funding on these regulatory milestones.
    • What is the reimbursement pathway? With regulatory approval achieved, revenue can only be achieved by executing a reimbursement strategy that addresses coverage, coding, and payment. After satisfying investors on the ability to secure coverage determination and coding, investors will focus on the pricing of a product to assess the sales potential.
    • Does the company have a clear inflection point it is trying to reach? If a life sciences company can’t articulate a specific, discrete strategy for how it will use the funding to develop or commercialize the product, investors may pass on the opportunity.
    • What is the competitive landscape? How big is the market opportunity in various jurisdictions? This evaluation should take into account not just the general consumer or patient pool, but also specific practicalities, such as the number of patients willing to pay a given price for the product, or the treatment paradigms that come into play. Having a good grasp of these specifics can improve conversations with potential investors, because it reduces the amount of uncertainty they will have to devote time and resources to address.
    • What is the exit opportunity? We often counsel our early-stage clients to “begin with the end in mind.” Life sciences investors will want to hear a clearly articulated vision of the exit. Will the company be seeking to access the capital markets in an initial public offering, looking for an exit through an acquisition, or seek to out-license the technology? In the case of an M&A exit or an out-license, companies should identify each of the potential suitors with whom they envision they will one day conduct a deal.

    Changing economic and political environments aside, the life sciences market presents exciting opportunities for early-stage life sciences companies and the investors who believe and invest in them. Early-stage firms with defined strategic goals, an innovative product addressing unmet need and a compelling value proposition, effective leadership, and above all, an exit strategy that enables investors to achieve the returns they are seeking, can position themselves to attract the right investors to bring their solutions to market. 


    Byron S. Kalogerou is the founder of the McDermott Will & Emery’s Life Science Industry Group and the senior attorney in the Boston Corporate Practice. He focuses his practice on domestic and cross-border mergers and acquisitions, finance, and joint ventures and alliances. He has substantial on-the-ground experience structuring mergers, acquisitions, divestitures, and joint ventures on six continents. Byron has extensive industry background in the life sciences, industrial, and manufacturing sectors. He also acts as outside general counsel to a number of companies.
    Related Searches
    • medical
    • needle
    • data
    • ai
    Suggested For You
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021 MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021
    Olympus Corporation Launches Powerseal Advanced Bipolar Surgical Energy Products Olympus Corporation Launches Powerseal Advanced Bipolar Surgical Energy Products
    Picarro Unveils EtO Gas Concentration Analyzer Picarro Unveils EtO Gas Concentration Analyzer
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board
    iNitrile iNitrile's Co-Founder Raises $33M for the Company
    Glooko’s Remote Patient Monitoring for Diabetics Glooko’s Remote Patient Monitoring for Diabetics
    Valencell’s Wearable Biomedical Sensors Valencell’s Wearable Biomedical Sensors
    Developing Next Generation Implants with Bioresorbables—A Medtech Makers Q&A Developing Next Generation Implants with Bioresorbables—A Medtech Makers Q&A
    Molding Modern Medtech Molding Modern Medtech
    FDA Clears 3NT Medical’s Peregrine Drivable ENT Scope FDA Clears 3NT Medical’s Peregrine Drivable ENT Scope
    Regulating IVDs and LDTs—Mike on Medtech Regulating IVDs and LDTs—Mike on Medtech
    Smaller Devices Require More Efficient Material Integration Smaller Devices Require More Efficient Material Integration
    Non-Profit Group Launches Initiative to Diversify Medtech Workforce Non-Profit Group Launches Initiative to Diversify Medtech Workforce

    Related Content

    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21

    • MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021

      MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021

      Attendees of The MedTech Conference, powered by AdvaMed, will vote for the Grand Prize winner.
      MedTech Innovator 09.21.21

    • Surgical
      Olympus Corporation Launches Powerseal Advanced Bipolar Surgical Energy Products

      Olympus Corporation Launches Powerseal Advanced Bipolar Surgical Energy Products

      Deliver consistent sealing reliability in an ergonomic, multifunctional design that promotes procedural efficiency.
      Olympus Corporation 09.21.21


    • Picarro Unveils EtO Gas Concentration Analyzer

      Picarro Unveils EtO Gas Concentration Analyzer

      Analyzers are now available for CEMS, stack testing, fenceline, and ambient monitoring systems.
      PR Newswire 09.20.21

    • Surgical
      Molli Surgical

      Molli Surgical's Breast Tumor Marker

      MPO's Sean Fenske speaks with Dr. Fazila Seker of MOLLI Surgical about the benefits of her company’s breast tumor marking system.
      Sean Fenske, Editor-in-Chief 09.14.21


      Trending
      • Quality Management Evolution: What to Expect in 2022
      • Dexcom Reportedly In Talks To Acquire Insulet | Medical Product Outsourcing
      • Shrinking Medical Devices Create Sizable Challenges For Micromolders | Medical Product Outsourcing
      • 5 Ways Plastics Revolutionized The Healthcare Industry | Medical Product Outsourcing
      • Prometheus Group Sued Over Reused Catheters And Rectal Sensors | Medical Product Outsourcing
      Breaking News
      • Anumana's ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status
      • inHEART's 3D Cardiac Modeling Tool Earns FDA Nod
      • FDA OKs RapidAI's Pulmonary Embolism Triage, Notification Tool
      • Kilo Health Invests 500,000 Euros in Pulsetto
      • China to Strengthen Robotic Surgical Market With Second 5-Year Plan
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Cybersecurity Challenges Leave Medical Device Makers Insecure
      • Contract Design for Medtech
      • Diabetes Medical Device Technology Update
      • Medtech Full-Service Outsourcing Q&A 2022

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Sets Goals to Reduce Greenhouse Gas Emissions, Unveils 2021 ESG Report
      Birla Carbon to Present Sustainable Carbon-based Solutions at PaintIndia 2022
      BTC Europe, NXTLEVVEL Biochem to Distribute Biobased & Biodegradable Solvents in Europe
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Anumana's ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status
      inHEART's 3D Cardiac Modeling Tool Earns FDA Nod
      FDA OKs RapidAI's Pulmonary Embolism Triage, Notification Tool
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Corealis CDMO Completes Deal with ArchiMed
      Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities
      Steriline Robotic Applications to Improve Quality in Drug Primary Packaging
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Glossier Announces New CEO
      Men’s Skincare Market to Hit $13 Billion by End of 2022
      Estée Lauder Promotes Gibu Thomas to EVP, ELC Online
      Happi

      Latest Breaking News From Happi

      Incorrect INCI Prompts Recall of Higher Education Vegan Lip Balm
      Hipdot Launches Girl Scout Cookie-Themed Makeup Collection
      Consumer Dermatology Company Dermala Introduces Second Microbiome-Powdered Line of Products for Eczema-Prone Skin
      Ink World

      Latest Breaking News From Ink World

      HP Indigo Reaches 2,000th Active Install
      Siegwerk Introduces New NC-Based Flexible Packaging Ink
      Sun Chemical Expands SunColorBox with SunConnect
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Thinx Names Meghan Davis as CEO
      Kimberly-Clark Reportedly Examining Sale of Latin American Tissue
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Extremity Medical Rolls Out OMNI Stable Ankle Fracture System
      James W. Stone Named AANA President
      Tom Hedman Named Senior Principal Scientist at Spinal Simplicity
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Canatu Receives IATF 16949:2016 Certification
      Applied Materials Announces 2Q 2022 Results
      ams OSRAM Supervisory Board to Elect Dr. Margarete Haase as Chairwoman

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login